ImmunoPrecise Antibodies (IPA) Competitors $0.49 -0.04 (-7.00%) As of 01/21/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends IPA vs. BYSI, RVPH, MURA, IMRX, GBIO, HOWL, CNTB, ELYM, NRXP, and FGENShould you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include BeyondSpring (BYSI), Reviva Pharmaceuticals (RVPH), Mural Oncology (MURA), Immuneering (IMRX), Generation Bio (GBIO), Werewolf Therapeutics (HOWL), Connect Biopharma (CNTB), Eliem Therapeutics (ELYM), NRx Pharmaceuticals (NRXP), and FibroGen (FGEN). These companies are all part of the "pharmaceutical products" industry. ImmunoPrecise Antibodies vs. BeyondSpring Reviva Pharmaceuticals Mural Oncology Immuneering Generation Bio Werewolf Therapeutics Connect Biopharma Eliem Therapeutics NRx Pharmaceuticals FibroGen BeyondSpring (NASDAQ:BYSI) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk. Which has higher earnings and valuation, BYSI or IPA? ImmunoPrecise Antibodies has higher revenue and earnings than BeyondSpring. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeyondSpring$1.88M36.62-$21.03MN/AN/AImmunoPrecise Antibodies$18.16M0.84-$20.13M-$0.78-0.63 Does the MarketBeat Community favor BYSI or IPA? BeyondSpring received 174 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 91.67% of users gave ImmunoPrecise Antibodies an outperform vote while only 66.79% of users gave BeyondSpring an outperform vote. CompanyUnderperformOutperformBeyondSpringOutperform Votes18566.79% Underperform Votes9233.21% ImmunoPrecise AntibodiesOutperform Votes1191.67% Underperform Votes18.33% Which has more risk and volatility, BYSI or IPA? BeyondSpring has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Do analysts recommend BYSI or IPA? ImmunoPrecise Antibodies has a consensus target price of $5.00, suggesting a potential upside of 914.20%. Given ImmunoPrecise Antibodies' stronger consensus rating and higher possible upside, analysts plainly believe ImmunoPrecise Antibodies is more favorable than BeyondSpring.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BYSI or IPA more profitable? BeyondSpring has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -114.50%. BeyondSpring's return on equity of 0.00% beat ImmunoPrecise Antibodies' return on equity.Company Net Margins Return on Equity Return on Assets BeyondSpringN/A N/A N/A ImmunoPrecise Antibodies -114.50%-73.74%-42.68% Does the media favor BYSI or IPA? In the previous week, ImmunoPrecise Antibodies had 5 more articles in the media than BeyondSpring. MarketBeat recorded 5 mentions for ImmunoPrecise Antibodies and 0 mentions for BeyondSpring. ImmunoPrecise Antibodies' average media sentiment score of 0.69 beat BeyondSpring's score of 0.00 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the news media. Company Overall Sentiment BeyondSpring Neutral ImmunoPrecise Antibodies Positive Do institutionals & insiders believe in BYSI or IPA? 40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 6.7% of ImmunoPrecise Antibodies shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryBeyondSpring and ImmunoPrecise Antibodies tied by winning 8 of the 16 factors compared between the two stocks. Get ImmunoPrecise Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPA vs. The Competition Export to ExcelMetricImmunoPrecise AntibodiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.31M$6.58B$5.39B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E Ratio-0.6310.0188.8317.53Price / Sales0.84335.611,283.2680.24Price / CashN/A22.6336.6032.90Price / Book0.535.084.964.69Net Income-$20.13M$154.90M$117.89M$224.57M7 Day Performance7.17%2.59%2.75%3.33%1 Month Performance23.25%1.52%3.63%5.33%1 Year Performance-66.69%5.49%27.27%22.97% ImmunoPrecise Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPAImmunoPrecise Antibodies3.3345 of 5 stars$0.49-7.0%$5.00+914.2%-66.7%$15.31M$18.16M-0.6380BYSIBeyondSpringN/A$1.64-1.2%N/A+100.0%$64.01M$1.88M0.0080Positive NewsGap DownRVPHReviva Pharmaceuticals3.796 of 5 stars$1.91+1.6%$11.25+489.0%-51.3%$63.87MN/A-1.725Analyst ForecastOptions VolumeNews CoverageGap UpMURAMural Oncology3.2994 of 5 stars$3.74-3.9%$16.00+327.8%-1.0%$63.66MN/A-0.41119Positive NewsGap DownIMRXImmuneering3.6472 of 5 stars$2.01-2.9%$12.80+536.8%-64.1%$62.41M$320,000.00-1.0260GBIOGeneration Bio4.1931 of 5 stars$0.92-0.6%$6.50+606.5%-42.8%$61.45M$18.58M-0.42150Positive NewsGap UpHOWLWerewolf Therapeutics3.1115 of 5 stars$1.35-2.2%$12.00+788.9%-67.8%$60.16M$3.39M-0.8840Positive NewsGap DownCNTBConnect Biopharma3.6129 of 5 stars$1.09+0.5%$8.00+636.9%+2.9%$59.98M$24.12M0.00110News CoveragePositive NewsHigh Trading VolumeELYMEliem TherapeuticsN/A$2.00+7.0%N/A-32.3%$59.50MN/A-3.7720High Trading VolumeNRXPNRx Pharmaceuticals2.8441 of 5 stars$4.91+1.2%$31.67+544.9%-91.7%$59.38MN/A-2.292FGENFibroGen2.5295 of 5 stars$0.59-4.4%N/A-30.5%$59.34M$180.02M-0.48570 Related Companies and Tools Related Companies BeyondSpring Alternatives Reviva Pharmaceuticals Alternatives Mural Oncology Alternatives Immuneering Alternatives Generation Bio Alternatives Werewolf Therapeutics Alternatives Connect Biopharma Alternatives Eliem Therapeutics Alternatives NRx Pharmaceuticals Alternatives FibroGen Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IPA) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
